We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
COMPARISON OF EFFICACY OF MILTEFOSINE VERSUS MEGLUMINE ANTIMONATE IN THE TREATMENT OF CUTANEOUS LEISHMANIASIS.
- Authors
Mohammad, Noor; Sagheer, Farah; Paracha, Mohammad Majid; Khan, Abdul Qayum; Naseem, Sadia; Wasim, Muhammad
- Abstract
Background: Cutaneous Leishmaniasis is a morbid condition that generates stigmatization and disfiguring scars. Pakistan is among the ninety-eight countries where cutaneous Leishmaniasis is endemic. Purpose of study was to compare the efficacy of miltefosine and meglumine antimoniate in the treatment of cutaneous Leishmaniasis. Methods: All patients with cutaneous Leishmaniasis (CL) who met the inclusion criteria were divided into two groups using the envelop method. Capsule Miltefosine 50 mg (2.5 mg/ kg) was given to group A, while intralesional Glucantime injection was given to group B. The treatment's efficacy was evaluated after four weeks and again after eight weeks. Results: Out of 74 patients, 37 patients were included in each group. In group A (miltefosine group), 56.75% were males, and 43.25% were females. In group B (meglumine antimoniate group), 62% were males, while 38% were females (p=0.63). The mean age was 32.81 years±12.09 SD, the mean duration of the disease was 5.4 months±2.3 SD and the mean number of lesions was 2.56±1.33 SD. The efficacy of Miltefosine and meglumine antimoniate (I/L) was 91.9% and 56.75%, respectively (p<0.001). Conclusion: Miltefosine was more effective than intralesional meglumine antimoniate in the treatment of cutaneous Leishmaniasis (p<0.001).
- Subjects
PAKISTAN; MILTEFOSINE; SKIN diseases; CUTANEOUS leishmaniasis; PHYSICIANS
- Publication
Journal of Ayub Medical College Abbottabad - Pakistan, 2022, Vol 34, Issue 4, p849
- ISSN
1025-9589
- Publication type
Article
- DOI
10.55519/JAMC-04-11135